Exodus Point Capital Management, LP Curis Inc Transaction History

Exodus Point Capital Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$0.74 - $15.01 $24,877 - $504,606	-33,618 Closed	0 $0
Q2 2022 Aug 19, 2022	SELL	$0.71 - $2.43 $313,092 - $1.07 Million	-440,975 Reduced 92.92%	33,618 $33,000
Q1 2022 May 13, 2022	BUY	$2.31 - $5.13 $692,200 - $1.54 Million	299,654 Added 171.29%	474,593 $1.13 Million
Q4 2021 Feb 11, 2022	BUY	$4.45 - $8.09 $778,478 - $1.42 Million	174,939 New	174,939 $833,000
Q2 2021 Aug 16, 2021	SELL	$7.45 - $16.27 $1.32 Million - $2.88 Million	-177,095 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$8.78 - $12.8 $1.26 Million - $1.84 Million	143,826 Added 432.31%	177,095 $2.01 Million
Q4 2020 Feb 16, 2021	BUY	$1.08 - $8.2 $22,684 - $172,232	21,004 Added 171.25%	33,269 $272,000
Q3 2020 Nov 16, 2020	BUY	$0.95 - $1.42 $11,651 - $17,416	12,265 New	12,265 $14,000

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $409M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.